UNOG-NEWS WHO COVID-19- Treatments - Remdesivir 20NOV2020
/
3:08
/
MP4
/
231.7 MB

Edited News | WHO

UNOG-NEWS WHO COVID-19- Treatments - Remdesivir 20NOV2020

COVID-19: UN health agency issues conditional advice against using remdesivir

Patients with COVID-19 should not be given the antiviral drug remdesivir “regardless of disease severity”, the UN World Health Organization (WHO) said on Friday.

Nonetheless, describing its recommendation as “conditional”, as opposed to “strong”, WHO stressed that data from a global trial on the efficacy of remdesivir was inconclusive, and that further trials should continue into its use for more vulnerable patients.

“We recommend a conditional recommendation – I want to highlight that - against the use of remdesivir in hospitalised patients with COVID-19 regardless of disease severity,” said Dr Janet Diaz, Head of Clinical Care at WHO, during a virtual press conference in Geneva.

According to data from the WHO-led Solidarity trial which was then examined by a panel of international experts behind the recommendation, “possibly remdesivir can lead to 29 fewer deaths per 1,000 patients or up to 11 more deaths per 1000 patients”, Dr Diaz said. “So you can see that …the confidence interval are relatively large…there was no evidence that there was any important effect on mortality, on the need for mechanical ventilation or the time to clinical improvement.”

But this did “not prove” that the antiviral “had no benefit at all”, Dr Diaz insisted. “There could still be potential small benefit, maybe in a health sub-group which is why the panel also recommended continued trials, continued enrolment into clinical trials.”

The WHO official explained that this might be “severe patients versus critical patients” or whether the antiviral is used “early versus late”.

Dr Bram Rochwerg, who was among the experts advising WHO, noted that there would likely be regional “variations” in the use of remdesivir.

While a minority of people will still choose to use it, the majority would not, based on the available data, he said.

“There may be groups (who might benefit) and the data was a bit more of a close call, so that’s why we felt strongly that trials need to continue using remdesivir and studying remdesivir and looking to see if there are specific groups that might, that might benefit,” he said. “We were very explicit that we do believe that these studies need to continue (and) Solidarity is continuing.”

Although the remdesivir development mirrors similar attempts to use other antivirals against the new coronavirus, Dr Diaz said there was no reason to lose hope in the fight against COVID-19.

“I do think there is a tremendous global effort to investigate treatments. You know, I think a lot of interest was done upfront with the repurposed of drugs, repurposed antivirals, you know we saw that with other repurposed drugs such as hydroxychloroquine, lopinavir, and there was a big push to try to test these and they’ve been tested and unfortunately, we just haven’t, you know, the results haven’t been as promising as we had hoped. But I don’t want to forget that we do have one lifesaving drug and even though it’s a repurposed old, old drug dexamethasone, a corticosteroid, we do know that that does reduce mortality, save lives of patient with severe and critical so there is something.”

Latest data from WHO indicates that eight in 10 people infected with COVID report mild symptoms, Dr Diaz said.

“Since the beginning (of the pandemic)…about 80 per cent of people have, you know, mild disease, a proportion maybe moderate disease and then only a small proportion, a smaller proportion, 20 per cent go on to develop severe or critical disease, and critical disease is a small, small portion, it’s five per cent or less, and that is…and that seems to be kind of consistent I think through the literature so most patients do have, if they have mild disease, self-limiting disease, they get better on their own, their immune system kicks in and they get better.”

Nonetheless, there are reports of more “persistent longer-term symptoms”, Dr Diaz noted. “So even though they don’t get severe disease there can be some persistent symptoms that lasts longer than one would have hoped for.”

  1. SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “We recommend a conditional recommendation - so I want to highlight that, it’s a conditional recommendation - against the use of remdesivir in hospitalized patients - with COVID-19, regardless of disease severity.”
  2. SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “Possibly remdesivir can lead to 29 fewer deaths par 1,000 patients or up to 11 more deaths per 1,000 patients so you can see that this is, the confidence interval is a little bit large.”
  3. SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “It was not clear that, there was no evidence, that there was any important effect on mortality, on the need for mechanic ventilation or the time to clinical improvement.”
  4. SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “This did not prove that remdesivir does not have a benefit at all and that’s why it is a conditional recommendation, there can still be potential small benefit, maybe in a health sub-group, which is why the panel also recommended continued trials, continued enrolment into clinical trials.”
  5. SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “You know, is there a sub-group that may benefit more – such as severe patients versus critical patients. Is there a timing in disease that may benefit more - such as early versus late - and those are all considerations that are in the guidelines.”
  6. SOUNDBITE (English) — Dr Bram Rochwerg, practising ITU clinician and expert adviser for WHO-led Solidarity Trial: “There may be groups and the data was a bit more of a close call, so that’s why we felt strongly that trials need to continue using remdesivir and studying remdesivir and looking to see if there are specific groups that might, that might benefit. And as she said, we were very explicit that we do believe that these studies need to continue, Solidarity is continuing, so.”
  7. SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “I do think there is a tremendous global effort to investigate treatments. You know, I think a lot of interest was done upfront with the repurposed of drugs, repurposed antivirals, you know we saw that with other repurposed drugs such as hydroxychloroquine, lopinavir, and there was a big push to try to test these and they’ve been tested and unfortunately, we just haven’t, you know, the results haven’t been as promising as we had hoped. But I don’t want to, I don’t want to forget that we do have one lifesaving drug and even though it’s a repurposed old, old drug dexamethasone, a corticosteroid, we do know that that does reduce mortality, save lives of patient with severe and critical so there is something.”
  8. SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “Since the beginning, is that about 80 per cent of people have, you know, mild disease, a proportion maybe moderate disease and then only a small proportion, a smaller proportion, 20 per cent go on to develop severe or critical disease, and critical disease is a small, small portion, it’s five per cent or less, and that is…and that seems to be kind of consistent I think through the literature so most patients do have, if they have mild disease, self-limiting disease, they get better on their own, their immune system kicks in and they get better.”
  9. SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “We do know that even patients with mild disease may have persistent longer-term symptoms. And that has been now described; so even though they don’t get severe disease there can be some persistent symptoms that lasts longer than one would have hoped for.”

Similar Stories

Middle East humanitarian update OCHA - UNHCR - WHO 22 November 2024

1

1

1

Edited News | OCHA , UNHCR , WHO

Middle East humanitarian update OCHA - UNHCR - WHO 22 November 2024 ENG FRA

The past two months of intensifying Israeli bombardment in Lebanon have been the “deadliest and most devastating” in decades as communities uprooted from the front line have continued to flee across the border to Syria, UN humanitarians said on Friday.

Crimes against journalists   Diego Luna and RSF - 20NOV2024 1

2

1

2

Edited News | UNOG

Crimes against journalists Diego Luna and RSF - 20NOV2024 1 ENG FRA

“State of Silence”: Diego Luna brings the fight to protect the press to the UN in Geneva 

Mexican actor, producer and director Diego Luna has brought his fight to protect journalists all the way to the United Nations, in Geneva. Together with documentary director Santiago Masa, he is putting a spotlight on the silencing of investigative journalism in his country, and on the incredibly high price that many journalist have to pay in pursuit of truth. 

UN Human Rights Spokesperson Jeremy Laurence on 1000 days since Russian Federation launched full-scale attack on Ukraine

1

1

1

Edited News | OHCHR , UNOG

UN Human Rights Spokesperson Jeremy Laurence on 1000 days since Russian Federation launched full-scale attack on Ukraine ENG FRA

Today marks the grim milestone of 1,000 days since the Russian Federation launched its full-scale armed attack on Ukraine. Our Office has verified that at least 12,162 civilians have been killed since 24 February 2022, among them 659 children. At least another 26,919 civilians have been injured,” UN Human Rights spokesperson Jeremy Laurance told the bi-weekly press briefing in Geneva.

UN Human Rights Spokesperson Jeremy Laurence on COP29

1

1

1

Edited News | OHCHR , UNOG

UN Human Rights Spokesperson Jeremy Laurence on COP29 ENG FRA

With COP29 in Baku now in its second - and final - week, UN Human Rights Chief Volker Türk has reiterated his call for urgent human rights-based climate action. 

Middle East update UNIFIL - UNICEF - WHO

1

1

1

Edited News | UNIFIL , UNICEF , WHO

Middle East update UNIFIL - UNICEF - WHO ENG FRA

Lebanon: Increased violence along Blue Line and ‘horrific new normal’ for children

In southern Lebanon, peacekeepers have witnessed “shocking” destruction of villages along the Blue Line and ever-deeper Israeli ground incursions, while the situation of children across the country is becoming increasingly desperate, the UN said on Tuesday.

UNRWA Press conference: Update on the situation in the occupied Palestinian territory (OPT) - 18 November 2024

2

1

2

Press Conferences , Edited News | UNRWA

UNRWA Press conference: Update on the situation in the occupied Palestinian territory (OPT) - 18 November 2024 ENG FRA

The head of the UN agency for Palestine refugees, UNRWA, confirmed on Monday that a large convoy of humanitarian aid was looted inside Gaza at the weekend, amid a near-total a breakdown in law and order and harassment of the agency’s staff by Israeli soldiers.

 

Ukraine 1000 days of war - OCHA 15 November 2024

1

1

1

Edited News | OCHA

Ukraine 1000 days of war - OCHA 15 November 2024 ENG FRA

In the nearly 1,000 days since Russia’s full-scale invasion of Ukraine, thousands of civilians have been killed, the country’s energy infrastructure is on the brink and drones terrify communities on the front line, the UN’s top aid official in the country said on Friday.

OHCHR: Safety of Journalists - 14 November 2024

2

1

2

Press Conferences , Edited News | OHCHR

OHCHR: Safety of Journalists - 14 November 2024 ENG FRA

Mexican actor, producer and director Diego Luna took a break from the big screen on Thursday to highlight the dangers faced by journalists in his country and beyond, condemning murders of reporters everywhere as “a scandal”.

Northern Gaza update - UNRWA 12 November 2024

1

1

1

Edited News | UNRWA

Northern Gaza update - UNRWA 12 November 2024 ENG FRA

Gaza: ‘People are losing hope’ as aid access is refused to north, warns UNRWA

Besieged northern Gaza is a place of dead bodies lying in the streets and hospitals running out of blood packs – a situation that’s “nothing short of catastrophic”, the UN agency for Palestinian refugees (UNRWA) said on Tuesday.

Gaza update report – OHCHR

1

1

1

Edited News | OHCHR

Gaza update report – OHCHR ENG FRA

UN Human Rights Spokesperson Jeremy Laurence & Ajith Sunghay, Head of UN Human Rights Office in the Occupied Palestinian Territory, on Gaza

Sudan crisis - UNHCR

1

1

1

Edited News | UNHCR

Sudan crisis - UNHCR ENG FRA

Sudan’s displaced have endured “unimaginable suffering” in their search for shelter from the country’s ongoing war, UN humanitarians warned on Friday.

Gaza health update - WHO

1

1

1

Edited News | WHO

Gaza health update - WHO ENG FRA

‘Exceptional achievement’: Humanitarians reach over 105,000 with polio vaccine in north Gaza

Despite ongoing attacks and access challenges, humanitarians have managed to inoculate over 105,000 children in north Gaza with the second and final dose of the oral polio vaccine, the UN World Health Organization (WHO) said on Tuesday.